JP2008516955A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516955A5 JP2008516955A5 JP2007536810A JP2007536810A JP2008516955A5 JP 2008516955 A5 JP2008516955 A5 JP 2008516955A5 JP 2007536810 A JP2007536810 A JP 2007536810A JP 2007536810 A JP2007536810 A JP 2007536810A JP 2008516955 A5 JP2008516955 A5 JP 2008516955A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- agent
- pparγ
- group
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003795 chemical substances by application Substances 0.000 claims 26
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 12
- 102000004877 Insulin Human genes 0.000 claims 11
- 108090001061 Insulin Proteins 0.000 claims 11
- 229940125396 insulin Drugs 0.000 claims 11
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 10
- 206010030113 Oedema Diseases 0.000 claims 9
- 102000000536 PPAR gamma Human genes 0.000 claims 9
- 108010016731 PPAR gamma Proteins 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 230000001235 sensitizing effect Effects 0.000 claims 7
- 230000004584 weight gain Effects 0.000 claims 7
- 235000019786 weight gain Nutrition 0.000 claims 7
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 4
- 229940100389 Sulfonylurea Drugs 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 4
- 229960003105 metformin Drugs 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 229940125542 dual agonist Drugs 0.000 claims 3
- 229960001601 obeticholic acid Drugs 0.000 claims 3
- 229960005095 pioglitazone Drugs 0.000 claims 3
- 229960004586 rosiglitazone Drugs 0.000 claims 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 2
- IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 claims 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 229950001135 muraglitazar Drugs 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 claims 2
- 229950004704 tesaglitazar Drugs 0.000 claims 2
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 claims 1
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 claims 1
- BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2r)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical group O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 claims 1
- DPRAYRYQQAXQPE-UHFFFAOYSA-N 2-bromohexadecanoic acid Chemical compound CCCCCCCCCCCCCCC(Br)C(O)=O DPRAYRYQQAXQPE-UHFFFAOYSA-N 0.000 claims 1
- NLUNAYAEIJYXRB-VYOQERLCSA-N 8(S)-HETE Chemical compound CCCCC\C=C/C\C=C/C=C/[C@@H](O)C\C=C/CCCC(O)=O NLUNAYAEIJYXRB-VYOQERLCSA-N 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 1
- PKNYXWMTHFMHKD-UHFFFAOYSA-N GW 7647 Chemical compound C1=CC(SC(C)(C)C(O)=O)=CC=C1CCN(C(=O)NC1CCCCC1)CCCCC1CCCCC1 PKNYXWMTHFMHKD-UHFFFAOYSA-N 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- WDXRGPWQVHZTQJ-AUKWTSKRSA-N Guggulsterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)/C(=C/C)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-AUKWTSKRSA-N 0.000 claims 1
- WDXRGPWQVHZTQJ-NRJJLHBYSA-N Guggulsterone E Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=O)C(=CC)[C@@]1(C)CC2 WDXRGPWQVHZTQJ-NRJJLHBYSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229950000700 guggulsterone Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- MYHXHCUNDDAEOZ-FOSBLDSVSA-N prostaglandin A2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O MYHXHCUNDDAEOZ-FOSBLDSVSA-N 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- WDXRGPWQVHZTQJ-UHFFFAOYSA-N trans-guggulsterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CC(=O)C(=CC)C1(C)CC2 WDXRGPWQVHZTQJ-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61938104P | 2004-10-14 | 2004-10-14 | |
| PCT/US2005/036536 WO2006044391A1 (en) | 2004-10-14 | 2005-10-14 | A method of reducing drug-induced adverse side effects in a patient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008516955A JP2008516955A (ja) | 2008-05-22 |
| JP2008516955A5 true JP2008516955A5 (https=) | 2009-03-26 |
Family
ID=36203284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536810A Withdrawn JP2008516955A (ja) | 2004-10-14 | 2005-10-14 | 患者において薬物誘発性の有害な副作用を軽減する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060252670A1 (https=) |
| EP (1) | EP1814582A4 (https=) |
| JP (1) | JP2008516955A (https=) |
| AU (1) | AU2005295888A1 (https=) |
| CA (1) | CA2584284A1 (https=) |
| WO (1) | WO2006044391A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| CA2578106C (en) | 2004-06-18 | 2015-09-01 | The University Of Queensland | Oedema detection |
| US20070190079A1 (en) * | 2004-10-29 | 2007-08-16 | Kalypsys, Inc. | Methods for the selective modulation of ppar |
| AU2006265763B2 (en) | 2005-07-01 | 2012-08-09 | Impedimed Limited | Monitoring system |
| CA2608962C (en) | 2005-07-01 | 2016-12-06 | Scott Chetham | Monitoring system |
| WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
| EP1886685A1 (en) * | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
| CA2670293C (en) * | 2006-11-30 | 2017-01-03 | Impedimed Limited | Measurement apparatus |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP3053440B1 (en) * | 2007-04-11 | 2020-08-12 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| EP2148613B9 (en) | 2007-04-20 | 2014-12-10 | Impedimed Limited | Monitoring system and probe |
| EP2162127A1 (en) * | 2007-05-24 | 2010-03-17 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Composition useful for the prevention of adverse effect due to the use of ppar-gamma agonists |
| AU2008207672B2 (en) | 2008-02-15 | 2013-10-31 | Impedimed Limited | Impedance Analysis |
| US20110105510A1 (en) * | 2008-06-17 | 2011-05-05 | Hiroshi Ishikawa | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| WO2011050393A1 (en) | 2009-10-26 | 2011-05-05 | Impedimed Limited | Fluid level indicator determination |
| WO2011060497A1 (en) | 2009-11-18 | 2011-05-26 | Impedimed Limited | Signal distribution for patient-electrode measurements |
| KR101567925B1 (ko) | 2010-04-08 | 2015-11-10 | 티더블유아이 바이오테크놀로지 인코포레이티드 | 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법 |
| CA2811634C (en) * | 2010-09-21 | 2019-01-15 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| EP2721418B1 (en) * | 2011-06-17 | 2020-08-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for determining a plasma volume variation and devices for implementing the method |
| NZ734451A (en) * | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| SI3043865T1 (sl) * | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| SI3071696T1 (sl) | 2013-11-22 | 2019-11-29 | Mina Therapeutics Ltd | C/EBP alfa kratko delujoči RNA sestavki in postopki uporabe |
| EA036404B1 (ru) * | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| CR20170456A (es) * | 2015-04-07 | 2018-06-13 | Intercept Pharmaceuticals Inc | Composiciones farmacéuticas para terapias combinadas |
| ES2980790T3 (es) | 2015-04-28 | 2024-10-03 | Basf As | Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
| JP7618384B2 (ja) * | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| US20210121493A1 (en) * | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| WO2019048632A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | STABILIZED COMPOSITIONS OF SMALL ACTIVATORY RNA (PARNA) OF HNF4A AND METHODS OF USE |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| IL308604B2 (en) | 2017-12-06 | 2025-08-01 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
| EA202190661A1 (ru) * | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| EP3999101A1 (en) * | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| JP2022548617A (ja) * | 2019-09-19 | 2022-11-21 | ノバルティス アーゲー | Ｆｘｒアゴニストを含む処置 |
| WO2025019330A1 (en) | 2023-07-14 | 2025-01-23 | Pleiogenix Inc. | Methods of treating fibrotic liver diseases or conditions with indeglitazar |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115728B1 (en) * | 1995-01-30 | 2006-10-03 | Ligand Pharmaceutical Incorporated | Human peroxisome proliferator activated receptor γ |
| CA2204616C (en) * | 1995-09-18 | 2002-12-17 | Ranjan Mukherjee | Ppar gamma antagonists for treating obesity |
| US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| JP2002532729A (ja) * | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | 核内受容体のリガンドのアッセイ |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| WO2002020463A2 (en) * | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
| ATE381542T1 (de) * | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| AU2003287965A1 (en) * | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
-
2005
- 2005-10-13 US US11/250,298 patent/US20060252670A1/en not_active Abandoned
- 2005-10-14 EP EP05807696A patent/EP1814582A4/en not_active Withdrawn
- 2005-10-14 AU AU2005295888A patent/AU2005295888A1/en not_active Abandoned
- 2005-10-14 WO PCT/US2005/036536 patent/WO2006044391A1/en not_active Ceased
- 2005-10-14 JP JP2007536810A patent/JP2008516955A/ja not_active Withdrawn
- 2005-10-14 CA CA002584284A patent/CA2584284A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516955A5 (https=) | ||
| US10342770B2 (en) | Treatment of NAFLD and NASH | |
| JP2020045362A5 (https=) | ||
| US20060252670A1 (en) | Method of reducing drug-induced adverse side effects in a patient | |
| JP6363104B2 (ja) | １５−ｏｈｅｐａを含む組成物および同組成物を使用する方法 | |
| KR102000332B1 (ko) | 간내 담즙정체성 질환의 치료 | |
| EP3880187A1 (en) | Treatment of obesity and its complications | |
| JP2009256392A5 (https=) | ||
| US10363235B2 (en) | Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same | |
| JP2010265315A (ja) | 癒着の予防及び／又は治療のための医薬 | |
| JP2017519028A5 (https=) | ||
| JP5020463B2 (ja) | ドナリエラ属（Ｄｕｎａｌｉｅｌｌａ）の粉末の治療的使用 | |
| AU2003299772B2 (en) | Association between a PPAR ligand and an antioxidant agent and use thereof for treating obesity | |
| WO2006011397A1 (ja) | 糖尿病の予防または治療のための薬剤 | |
| JPWO2002066030A1 (ja) | ジクロフェナクとオルノプロスチルからなる医薬組成物 | |
| JP2022546987A5 (https=) | ||
| CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
| Penner et al. | Resolution of multiple severe nonsteroidal anti‐inflammatory drug‐induced colonic strictures with prednisone therapy: a case report and review of the literature | |
| JPWO2008105181A1 (ja) | 下部尿路症状の予防及び／又は治療のための医薬 | |
| US20250360215A1 (en) | Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases | |
| JP4433496B2 (ja) | Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用 | |
| WO2023026130A1 (en) | Pharmaceutical combination of ppar agonist(s) and sterol absorption inhibitor(s) and use thereof | |
| IL310994A (en) | Compositions and methods for preventing or reducing the risk of metabolic syndrome | |
| WO2005117855A1 (ja) | 糖尿病の予防または治療のための薬剤 | |
| TW201304769A (zh) | 降低血脂異常病患之糖化血色素的醫藥組成物 |